Antibiotic resistance is increasing worldwide, and it has been regarded as the main factor reducing the efficacy of Helicobacter pylori therapy. The aim of this study was to determine the phenotype and genotype of antibiotic-resistant strains of H. pylori in the Malaysian population and to evaluate the impact of antibiotic resistance to eradication outcome. One hundred and sixty-one H. pylori isolates were analysed in this study. Metronidazole, clarithromycin, fluoroquinolone, amoxicillin and tetracycline susceptibilities were determined by Etest. PCR followed by DNA sequencing was carried out to determine mutations. The medical records of the patients infected with resistant strains were reviewed to determine the eradication outcome. Metronidazole resistance was encountered in 36.6 % of H. pylori isolates, whereas clarithromycin and fluoroquinolone resistance was observed in 1.2 and 1.9 % of isolates, respectively. All strains tested were susceptible to amoxicillin and tetracycline. Frameshift and nonsense mutations in rdxA and frxA genes resulting in stop codons contributed to metronidazole resistance, which leads to reduced eradication efficacy. A2142G and A2143G mutations of 23S rRNA were identified as causing failure of the eradication therapy. Mutation at either codon 87 or 91 of the gyrA gene was identified in fluoroquinolone-resistant strains. However, the effect of resistance could not be assessed. This study showed that frameshift and nonsense mutations in rdxA or frxA genes and point mutations in the 23S rRNA affected the efficacy of H. pylori eradication therapy.
INTRODUCTION
Helicobacter pylori infection is usually acquired in childhood and infects approximately 50 % of the world population. The infection is chronic in nature, leading to gastritis and may result in complications such as peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue lymphoma (Atherton, 2006) . As H. pylori infection is a risk factor for gastric cancer, it is therefore recommended that treatment be given to infected individuals with the aim of eradicating the infection. The Maastricht III Consensus Report recommends triple therapy using a proton pump inhibitor (PPI) combined with clarithromycin and amoxicillin or metronidazole as first-line agents for the eradication of H. pylori (Malfertheiner et al., 2007) . However, standard triple therapy for H. pylori infection has limited efficacy, because of side effects, poor compliance of patients to therapy and, more importantly, the development of antimicrobial resistance. The fluoroquinolone group of antibiotics is considered an alternative and is often recommended following failure with first-line therapy (Chisholm & Owen, 2009; Gisbert, 2009 ).
The reported prevalence of resistance to clarithromycin, metronidazole, fluoroquinolones and amoxicillin varies widely among geographical areas (De Francesco et al., 2010a) . Furthermore, a decline in eradication rates of H. pylori has been noted and reported from various countries, primarily due to emerging antibiotic-resistant isolates (De Francesco et al., 2010b; Hwang et al., 2010; Bago et al., 2010) . The increasing prevalence of H. pylori strains resistant to commonly used antimicrobials negatively affects eradication of H. pylori infection, and may lead to serious problems for the treatment of H. pylori-related disorders in the near future. Knowledge of the mechanisms of resistance would help with more rational antibiotic combinations, with the aim of improving treatment success and outcomes. In Malaysia, antibiotic resistance of H. pylori has been reported by Ahmad et al. (2011) ; however, the study did not include data on the impact of the resistance phenotype/ genotype on the patient's eradication outcome. Therefore, we carried out this study to determine the molecular characteristics of antibiotic resistance, and evaluate the impact of both resistance phenotype and genotype on eradication outcome. Indians and 1 of other ethnicity, with an age range of 17 to 89 years old. Forty-two patients were males and fifty-seven were females. Antrum and corpus biopsies from the stomach were obtained from 62 patients, corpus biopsies from 19 patients and antrum biopsies from 18 patients.
METHODS
H. pylori culture. Biopsies were subcultured for H. pylori on Columbia agar base (Oxoid) containing Dent's supplement (Oxoid) and 7 % defibrinated sheep blood. The plates were incubated at 37 uC for 5 days under microaerophilic conditions. Antibiotic-susceptibility testing. The Etest method was used to determine the MIC of metronidazole, clarithromycin, levofloxacin, ciprofloxacin, amoxicillin and tetracycline using Etest strips (AB Biodisk). H. pylori culture suspension with a McFarland turbidity of 3.0 was used to inoculate Columbia agar supplemented with 7 % defibrinated sheep blood. The plates were then incubated at 37 uC for 5 days under microaerophilic conditions. Isolates were classified as resistant when the MIC value was: .1 mg l 21 for levofloxacin and ciprofloxacin (Kim et al., 2005) ; ¢1 mg l 21 for clarithromycin; .8 mg l 21 for metronidazole and amoxicillin; and ¢2 mg l 21 for tetracycline (Kim et al., 2001; Mégraud & Lehours, 2007) .
DNA extraction and genotyping of resistance genes. DNA was extracted using a Nucleospin tissue kit (Macherey-Nagel, BD Biosciences) and stored at 220 uC until use. The rdxA and frxA genes were amplified by PCR using specific primers, as described elsewhere (Solcà et al., 2000; Chisholm & Owen, 2004) . Amplification of the 23S rRNA gene was carried out using a protocol as described by Ahmad et al. (2009) . The quinolone-resistance-determining regions of gyrA and gyrB were amplified using primers as described by Tankovic et al. (2003) . PCR was performed in a GeneAmp PCR system 2400 thermal cycler (Perkin Elmer). The amplified products were purified using a QIAquick PCR purification kit (Qiagen). The amplicons were sequenced in a ABI PRISM 377 genetic analyzer (Applied Biosystems) using a BigDye terminator v3.1 sequencing kit. All the sequences were aligned and analysed using free CLUSTAL W software (http://www.ebi. ac.uk/Tools/msa/). Each isolate of H. pylori was characterized by the assignment of a susceptibility pattern based on its combined susceptibilities to metronidazole, clarithromycin and levofloxacin. Overall, 60.2 % (97) of the isolates were susceptible to all antibiotics. Resistance to metronidazole was only identified in 36.6 % (59) of the isolates. One isolate was resistant to both metronidazole and clarithromycin. Resistance to either clarithromycin or levofloxacin was identified in one isolate each, whereas two isolates were resistant to both metronidazole and levofloxacin.
RESULTS

Mutation analysis of the resistance genes
A total of 49 of the rdxA genes obtained from metronidazolesensitive (18 isolates) and metronidazole-resistant strains (31 isolates) were sequenced. As shown in Table 2 , frameshift mutations were found in five (16.1 %) cases, whilst nonsense mutations were found in six (19.4 %) of the rdxA cases, from the resistant strains only. Twenty (64.5 %) of the metronidazole-resistant strains carried missense mutation in the rdxA gene. All metronidazole-sensitive strains (n518) exhibited an amino acid substitution (missense mutation). Mutation types in the frxA gene (missense, frameshift and nonsense) were distributed among sensitive and resistant strains, with predominantly frameshift mutations among resistant strains. The ORF of the frxA gene in 10 antibiotic-resistant H. pylori isolates was disrupted by a deletion of nt 54 and 208. These events led to the occurrence of a stop codon at positions corresponding to amino acid 39 (5 isolates), 54 (2 isolates), 74 (2 isolates) or 80 (1 isolates). One isolate exhibited a nonsense mutation due to a codon substitution from glutamine to a stop codon at amino acid position 5.
The mutation in the 23S rRNA was determined in 15 H. pylori isolates (13 clarithromycin-sensitive isolates and 2 clarithromycin-resistant isolates). Three types of mutations were identified, i.e. A2142G, A2143G and T2182C. A2142G and A2143G mutations were found in clarithromycinresistant isolates (one isolate each) and T2182C was detected in all clarithromycin-sensitive isolates.
Eight gyrA and gyrB genes were sequenced from five fluoroquinolone-sensitive and three fluoroquinoloneresistant isolates. Point mutations in the gyrA gene at codon 87 Asn or 91 Asp were detected in fluoroquinoloneresistant isolates. Among fluoroquinolone-sensitive isolates, five isolates showed no mutation in the gyrA gene and one isolate had dual substitutions of Gln85ASer and Ala88AThr. For the gyrB gene, dual substitutions (Asp481AGlu and Arg484ALys) were identified in one fluoroquinolone-sensitive and one fluoroquinolone-resistant isolate. No mutation of gyrB was found in five fluoroquinolone-sensitive and one fluoroquinolone-resistant isolate tested.
Effect of infection with antibiotic-resistant strains of H. pylori on eradication outcome
The medical records of the 43 patients infected with antibiotic-resistant H. pylori strains were reviewed to determine the effect of infection on eradication outcomes. Thirty-three patients' records were available for review, whilst ten records were not available. Out of the 33 patients, 23 of them were given standard first-line triple therapy for H. pylori eradication. This consisted of a PPI, 500 mg clarithromycin and 1 g amoxicillin given twice daily for a total duration of 7 days. Eradication therapy was not given to the rest of 10 patients due to negative urea breath test results prior to OGDS, and the patients were given PPI only or were investigated for other underlying diseases. From the 23 patients, a total of 39 H. pylori were isolated (as shown in Table 3 ) with the distribution as follows: H. pylori were isolated from the antrum and corpus of 15 patients, 5 strains of H. pylori were from the corpus only (2 H. pylori strains were isolated from different sites of the corpus of one patient) and 4 H. pylori strains were isolated from the antrum only. In addition, the medical records of the 18 patients infected with susceptible H. pylori strains were also reviewed. These patients received the same H. pylori eradication regimen as stated above. H. pylori had been successfully eradicated from 16 patients (69.9 %) who were infected with antibiotic-resistant strains of H. pylori, whereas eradication failure was identified in 30.4 % (7 out of 23) patients. However, H. pylori eradication was achieved in all patients with susceptible strains.
As far as the metronidazole-resistance genotype is concerned, the data showed that patients who were infected with a mixed resistant strain (a different mutation type in rdxA and frxA genes) were less frequently cured as compared with those patients infected with pure resistant strains (the same mutation type in rdxA and frxA genes). Unsuccessful eradication was identified in 57.1 % of patients (4 out of 7) infected with antibiotic-resistant H. pylori strains harbouring different mutations in the rdxA and frxA genes (patient nos 1, 7, 8 and 12), whereas successful eradication was identified in all patients infected with resistant H. pylori harbouring a missense mutation in both rdxA and frxA genes (patient nos 4, 16, 17 and 19). When the results were analysed according to metronidazole-resistance phenotype, the eradication rate was higher in the case of susceptibility (100 %; 18 out of 18) versus in the case of resistance (75 %; 15 out of 20).
The presence of the A2142G or A2143G point mutation in 23S rRNA was associated with the clarithromycin-resistance phenotype and correlated with eradication failure (patient nos 3 and 22). Since levofloxacin resistance occurred in only one patient, it is difficult to assess the impact of the gyrA mutation on the eradication outcome in this study.
DISCUSSION
The study showed that all the H. pylori isolates were susceptible to amoxicillin and tetracycline. Sixty-four Among macrolides, clarithromycin has been shown to be superior. The rate of resistance to clarithromycin is consistently much lower than that to metronidazole. An increase resistance rate from 8.6 to 20.7 % was detected in Shanghai, China, from 2000 to 2009 (Sun et al., 2010) . In Europe, the global prevalence rate of clarithromycin resistance was between 5 and 20 % (Mégraud, 2004) . The prevalence of clarithromycin resistance (1.2 %) observed in the present study is comparable to that observed in the Netherlands (1.7 %) (Debets-Ossenkopp et al., 1999).
Levofloxacin, a new broad-spectrum antibiotic with a strong antimicrobial activity, has been used to eradicate H. pylori in recent years. The guidelines have recommended levofloxacin-containing therapies as first-line therapy and rescue therapy as they have good efficacy. However, it was reported that resistance of H. pylori to levofloxacin is high in many parts of the world (De Francesco et al., 2010a; Sun et al., 2010) . We are concerned with the occurrence of resistance to fluoroquinolones (i.e. levofloxacin) in H. pylori isolated from our community, as the antibiotic is currently used as a second-line therapy in Universiti Kebangsaan Malaysia Medical Centre. Fortunately, the resistance rate is still low.
In the present study, the majority of the isolates showed high MIC values for metronidazole. Although the resistance rate to metronidazole is higher compared to other antibiotics used for H. pylori eradication in the Malaysian population, the MIC 50 of metronidazole is still low (0.5 mg l
21
). In addition, the MIC 50 for all the antibiotics tested showed the susceptibility of the H. pylori. A high MIC 90 was only detected for metronidazole, whereas other antibiotics tested were shown to be within the susceptible range. This indicates that the main antibiotic components in the triple therapy (metronidazole, clarithromycin and levofloxacin) are still relevant for H. pylori eradication in our Malaysian population. The majority of the isolates were resistant to a single antibiotic and dual resistance was identified in only three isolates.
Metronidazole resistance occurs mainly by mutations in the rdxA gene of H. pylori, which encodes an enzyme that reduces metronidazole to active metabolites. Different mutations involving the rdxA gene, which encodes an oxygen insensitive NADPH nitroreductase, have been identified in metronidazole-resistant strains. Moreover, other genes such as frxA also seemed to be involved (Marais et al., 2003) . Mutations in the frxA gene, encoding an NAD(P)H flavin reductase showing high homology with the rdxA product, can also affect metronidazole susceptibility (Kwon et al., 2000) . In the present study, missense mutation of rdxA gene was identified in all sensitive strains, as well as 64.5 % of resistant strains. Frameshift and nonsense mutations were implicated in 16.1 and 19.4 % of the resistant strains, respectively. Amino acid substitutions were found among both susceptible and resistant strains, and we could not ascribe particular missense mutations to the resistance phenotype. It is noteworthy that the frameshift and nonsense mutations in the rdxA gene that resulted in truncated protein were detected only in resistant strains and could contribute to metronidazole resistance. Missense mutations and resultant amino acid substitutions may alter the function of RdxA and preclude reductive activation. As shown in our study, the combination of missense mutation in the rdxA gene and frameshift mutation in the frxA gene resulted in eradication failure as identified in three patients (Table 3 ). There is evidence that these point mutations in frxA genes are able to increase bacterial resistance exclusively in the presence of rdxA gene mutations (Matteo et al., 2006) . Frameshift mutation of the frxA gene was detected in the majority of the resistant strains (11 of 13) and may contribute to metronidazole resistance. The absence of a single universal mutation in rdxA and frxA genes associated with metronidazole resistance in Malaysian isolates supports findings reported from other countries (Llanes et al., 2010; Chisholm & Owen, 2003) . Mutations resulting in a stop codon could be critical to the metronidazole-resistance phenotype. The distribution of missense mutations in rdxA and frxA genes among sensitive and resistant strains of our local H. pylori suggests that this mutation played no significant role in resistance to metronidazole.
The MIC of metronidazole for the majority of these resistant strains was .256 mg l 21 suggesting that there was no clear correlation between the types of mutation identified and the level of resistance. In addition, we were unable to correlate the mutation type of any Malaysian isolate with MIC value as all clarithromycin-or fluoroquinolone-resistant isolates exhibited a similar MIC.
Resistance of H. pylori to clarithromycin is usually due to mutation in the 23S rRNA gene and considerably reduces the success rate of standard triple therapies (De Francesco et al., 2010b) . Several mutations have been detected, and it has been found that three point mutations, namely A2143G, A2142G and A2142C, are responsible for .90 % cases of primary resistance to clarithromycin in H. pylori strains (Wueppenhorst et al., 2009; De Francesco et al., 2007) . In Korea, T2182C mutations were also identified in primary clarithromycin-resistant strains (Kim et al., 2008) , although the role of this mutation has been controversial. Analysis of clarithromycin-resistant H. pylori strains in our population revealed that point mutation in the peptidyltransferase domain of the 23S rRNA is the mechanism of resistance, and adenine to guanine transition mutations at position 2142 or 2143 were identified. In our study, mutation at T2182C was detected in all clarithromycinsensitive isolates, but not detected in clarithromycinresistant isolates. These results suggest that T2182C does not play a role in clarithromycin resistance.
Fluoroquinolones are considered safe oral drugs with good anti-helicobacter activity. Molecular markers for fluoroquinolone resistance in H. pylori are well documented (Cattoir et al., 2007; Rajper et al., 2012) and we identified that Malaysian isolates with the fluoroquinolone-resistance phenotype contained mutations in the quinolone-resistance-determining region of the gyrA gene. Mutations in both the 91 and 87 position have been observed in our fluoroquinolone-resistant isolates. No gyrB mutation was identified in the majority of the isolates tested, indicating that gyrB has no impact on fluoroquinolone resistance.
Although the genotypes of antibiotic resistance have been described, so far the effect of these genotypes on the eradication efficacy has not been evaluated. In this study, bacterial eradication was achieved in all four patients infected with metronidazole-resistant strains harbouring missense mutations in both rdxA and frxA genes, suggesting that the mutations did not affect H. pylori eradication therapy. Furthermore, patients infected with metronidazolesusceptible strains achieved successful eradication. However, the presence of the metronidazole-resistance phenotype or mutation in either the rdxA or the frxA gene that resulted in occurrence of a stop codon reduces the eradication rates.
In the present study, A2142G and A2143G mutations of 23S rRNA were detected only in the clarithromycin-resistant strains, and the eradication rate in the patients infected with H. pylori harbouring this mutation was 0 % (0/2). Although the number of patients infected with clarithromycinresistant strains was small, the results suggest that A2142G and A2143G are important 23S rRNA mutations, associated with clarithromycin resistance and correlated with H. pylori eradication efficacy. A study by Lee et al. (2005) showed that bacterial eradication failure correlated completely with A2142G and A2143G mutations. As shown in our study, clarithromycin resistance was 100 % predictive of treatment failure. This showed that the resistance to clarithromycin was critical to the effectiveness of H. pylori eradication with triple therapy. Even though the prevalence of clarithromycin resistance is low in our study, the presence of resistance (either phenotypic or genotypic) was shown to be responsible for treatment failure.
Nevertheless, this study had some limitations. In the study, we determined the resistance genotype using isolated strains rather than gastric biopsy specimens. Therefore, the determination of the resistance genotype took longer, until after the culture of the H. pylori was available. In addition, the medical record of some patients was not traceable, since these patients were recruited in the study a few years back. The strength of our study was that we managed to demonstrate the presence of the metronidazole-resistance genotype (frameshift and nonsense mutations in rdxA and frxA genes) and phenotype that resulted in reduced eradication rates. In addition, the presence of a phenotype or genotype of clarithromycin resistance resulted in treatment failure. Furthermore, a large-scale study of the patient population is needed to further confirm the effect of the phenotype and genotype of H. pylori antibiotic-resistant strains on eradication outcome, especially in our population where data are still lacking.
The findings from this study highlight the importance of determining the genotype of antibiotic-resistant strains to enable health providers to choose an appropriate regimen for a higher eradication outcome. The data on the resistance genotypes of H. pylori provided here are critical for guiding clinicians in the selection of appropriate antibiotics for the treatment of H. pylori infection.
In conclusion, this study demonstrated that the prevalence of H. pylori strains resistant to metronidazole is high in our region. H. pylori isolates harbouring frameshift and nonsense mutations in the rdxA and frxA genes resulted in a reduction in the effectiveness of the eradication therapy as compared to missense mutation in both genes. A low prevalence of resistance to clarithromycin and levofloxacin was detected among our H. pylori clinical isolates. However, mutation in 23S rRNA gene detected in clarithromycinresistant strains resulted in a complete failure of the eradication therapy. Based on these findings we suggest that the genotype of the implicated H. pylori is determined prior to administration of metronidazole and clarithromycin for eradication therapy.
